Aritzia's growth story underappreciated by market, UBS argues
Aritzia Inc (TSX:ATZ) remains an "EPS compounder" whose long-term growth story is being underappreciated by investors focused on near-term comp sales...
Latest
810 stories · page 15 of 68
EchoStar shares rise as UBS says SpaceX stake makes stock undervalued
EchoStar (NASDAQ:ECHO) shares got a boost Tuesday after UBS resumed coverage of the stock with a Buy rating and a $150 price target, sending the stock up...
Qualcomm shares jump on Amazon AI chip partnership
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) and Amazon.com Inc (NASDAQ:AMZN) on Tuesday announced a multi-generation collaboration to develop customized silicon...
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR...
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
Domestic Metals commences drilling at Rio Tinto joint venture Smart Creek project
Domestic Metals Corp (TSX-V:DMCU, OTCQB:DMCUF, FRA:03E0) has kicked off a 9,000-metre diamond drill program at its Smart Creek Project in Montana, targeting...
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson’s disease...
